[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2009149205A3 - Cell lines that secrete soluble vegf receptors and uses thereof - Google Patents

Cell lines that secrete soluble vegf receptors and uses thereof Download PDF

Info

Publication number
WO2009149205A3
WO2009149205A3 PCT/US2009/046163 US2009046163W WO2009149205A3 WO 2009149205 A3 WO2009149205 A3 WO 2009149205A3 US 2009046163 W US2009046163 W US 2009046163W WO 2009149205 A3 WO2009149205 A3 WO 2009149205A3
Authority
WO
WIPO (PCT)
Prior art keywords
vegf receptors
receptors
cell lines
vegf
soluble vegf
Prior art date
Application number
PCT/US2009/046163
Other languages
French (fr)
Other versions
WO2009149205A2 (en
Inventor
Weng Tao
Konrad Kauper
Paul Stabila
Original Assignee
Neurotech Usa, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurotech Usa, Inc. filed Critical Neurotech Usa, Inc.
Publication of WO2009149205A2 publication Critical patent/WO2009149205A2/en
Publication of WO2009149205A3 publication Critical patent/WO2009149205A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention provides isolated nucleic acid and polypeptide sequences encoding Vascular Endothelial Growth Factor (VEGF) receptors, such as soluble VEGF receptors. Also encompassed are cell lines encoding such VEGF receptors. The invention also provides encapsulated cell therapy devices that are capable of delivering such VEGF receptors as well as methods of using these devices to deliver the VEGF receptors to the eye and to treat ophthalmic and cell proliferation disorders in patients suffering therefrom.
PCT/US2009/046163 2008-06-03 2009-06-03 Cell lines that secrete soluble vegf receptors and uses thereof WO2009149205A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5839808P 2008-06-03 2008-06-03
US61/058,398 2008-06-03

Publications (2)

Publication Number Publication Date
WO2009149205A2 WO2009149205A2 (en) 2009-12-10
WO2009149205A3 true WO2009149205A3 (en) 2010-04-01

Family

ID=41398849

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/046163 WO2009149205A2 (en) 2008-06-03 2009-06-03 Cell lines that secrete soluble vegf receptors and uses thereof

Country Status (1)

Country Link
WO (1) WO2009149205A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2750027C (en) 2009-01-23 2020-11-10 Nsgene A/S Improved cell lines and their use in encapsulated cell biodelivery
CA2812707C (en) 2010-09-27 2020-02-18 Nsgene A/S Implantable cell device with supportive and radial diffusive scaffolding
EP2646007B1 (en) 2010-12-02 2016-12-21 Neurotech USA, Inc. Cell lines that secrete anti-angiogenic antibody-scaffolds and soluble receptors and uses thereof
WO2013181424A1 (en) * 2012-05-30 2013-12-05 Neurotech Usa, Inc. Cryopreserved implantable cell culture devices and uses thereof
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
KR20180104635A (en) 2015-12-30 2018-09-21 코디악 사이언시스 인코포레이티드 Antibodies and conjugates thereof
AU2019227997A1 (en) 2018-03-02 2020-09-24 Kodiak Sciences Inc. IL-6 antibodies and fusion constructs and conjugates thereof
EP4041312A4 (en) 2019-10-10 2023-12-20 Kodiak Sciences Inc. Methods of treating an eye disorder

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712380A (en) * 1993-03-25 1998-01-27 Merck & Co., Inc. DNA encoding a soluble VEGF inhibitor
US6270993B1 (en) * 1995-10-07 2001-08-07 Toa Gosei Co., Ltd. VEGF-binding polypeptide
US20050175610A1 (en) * 1999-06-08 2005-08-11 Wiegand Stanley J. Modified chimeric polypeptides with improved pharmacokinetic properties and methods of making and using thereof
US20060030000A1 (en) * 2004-03-05 2006-02-09 Ludwig Institute For Cancer Research Growth factor binding constructs materials and methods
WO2006043972A1 (en) * 2004-10-12 2006-04-27 Amprotein Corporation Chimeric protein
US20070071734A1 (en) * 1999-04-06 2007-03-29 Weng Tao ARPE-19 as platform cell line for encapsulated cell-based delivery

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712380A (en) * 1993-03-25 1998-01-27 Merck & Co., Inc. DNA encoding a soluble VEGF inhibitor
US20070010442A1 (en) * 1993-03-25 2007-01-11 Kendall Richard L Inhibitor of vascular endothelial cell growth factor
US6270993B1 (en) * 1995-10-07 2001-08-07 Toa Gosei Co., Ltd. VEGF-binding polypeptide
US20070071734A1 (en) * 1999-04-06 2007-03-29 Weng Tao ARPE-19 as platform cell line for encapsulated cell-based delivery
US20050175610A1 (en) * 1999-06-08 2005-08-11 Wiegand Stanley J. Modified chimeric polypeptides with improved pharmacokinetic properties and methods of making and using thereof
US20060030000A1 (en) * 2004-03-05 2006-02-09 Ludwig Institute For Cancer Research Growth factor binding constructs materials and methods
WO2006043972A1 (en) * 2004-10-12 2006-04-27 Amprotein Corporation Chimeric protein

Also Published As

Publication number Publication date
WO2009149205A2 (en) 2009-12-10

Similar Documents

Publication Publication Date Title
WO2009149205A3 (en) Cell lines that secrete soluble vegf receptors and uses thereof
WO2012075184A3 (en) Cell lines that secrete anti-angiogenic antibody-scaffolds and soluble receptors and uses thereof
PH12015501806A1 (en) Novel benzopyran kinase modulators
WO2013084000A3 (en) Exosomes for delivery of biotherapeutics
WO2008101985A3 (en) Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
MX2020008274A (en) Methods and compositions for therapeutic protein delivery.
WO2010003268A3 (en) Methods and compositions for enhanced delivery of macromolecules
CA2711696C (en) Therapeutic compositions for treatment of ocular inflammatory disorders
WO2009120717A3 (en) Pyrido [3, 4-b] indoles and methods of use
EP4371615A3 (en) Treatment of amd using aav sflt-1
WO2014062697A3 (en) Drug delivery conjugates containing unnatural amino acids and methods for using
EA025281B9 (en) 3,5-DISUBSTITUED-3H-IMIDAZO[4,5-b]PYRIDINE AND 3,5-DISUBSTITUED-3H-[1,2,3]TRIAZOLO[4,5-b]PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN KINASES
WO2007044534A3 (en) Vegf analogs and methods of use
WO2012012772A3 (en) Drug eluting hydrogels for catheter delivery
MY169987A (en) Selective pi3k delta inhibitors
UA105290C2 (en) APTAMERS TO β-NGF AND THEIR USE IN TREATING β-NGF MEDIATED DISEASES AND DISORDERS
MX2013006040A (en) Lysophosphatidic acid receptor antagonists and their use in the treatment fibrosis.
WO2010127177A8 (en) Pyrido [4,3-b] indoles and methods of use
WO2013040309A3 (en) Wnt compositions and therapeutic uses of such compositions
WO2011147981A3 (en) Neuregulin isoforms, neuregulin polypeptides and uses thereof
WO2012083302A3 (en) Compositions and methods for the treatment or prevention of human adenovirus-36 infection
EP2700708A3 (en) Enhancing the T-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and its use in vaccination
WO2010040023A3 (en) Methods and compositions for protein delivery
WO2009009587A3 (en) Apoptosis-modulating protein therapy for proliferative disorders and nanoparticles containing the same
WO2012160333A3 (en) Recombinant yeast expressing human h- ferritin

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09759364

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09759364

Country of ref document: EP

Kind code of ref document: A2